세계의 성장호르몬 결핍증 시장 규모, 점유율, 성장 분석 : 유형별, 진단별, 치료별, 투여 경로별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Growth Hormone Deficiency Market Size, Share, and Growth Analysis, By Type, By Diagnosis, By Treatment, By Route of Administration, By End User, By Region - Industry Forecast 2025-2032
상품코드:1701016
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 04월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
성장호르몬 결핍증 시장 규모는 2023년 37억 달러, 2024년 39억 달러에서 2032년 59억 9,000만 달러로 성장하고, 예측 기간(2025-2032년) 동안 5.5%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
유전자 질환, 뇌 손상, 특정 치료 등의 요인으로 인해 성장호르몬 결핍증(GHD)의 발병률이 증가함에 따라 성장호르몬 치료에 대한 수요가 크게 증가하고 있습니다. 미국 국립생물공학정보센터(NCBI)의 자료에 따르면, 영국에서는 약 3,500-4,000명 중 1명이 소아 GHD를 앓고 있어 효과적인 치료법에 대한 수요가 증가하고 있습니다. 이러한 유병률 증가로 인해 업계가 성장하고 있으며, 그 선두에는 강력한 연구 개발이 있습니다.2022년 2월 화이자와 OPKO가 주 1회 투여하는 NGENLA(TM)(somatrogon) 주사제의 유럽연합(EU) 판매 승인을 받은 것은 성장 호르몬 치료의 성장호르몬 치료의 전망에 있어 중요한 이정표이자 업계의 성장 궤도를 더욱 견고히 하는 계기가 되었습니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 분석
성장호르몬 결핍증 시장 규모 : 유형별
시장 개요
소아 성장호르몬 결핍증
성인 성장호르몬 결핍증
성장호르몬 결핍증 시장 규모 : 진단별
시장 개요
혈액 검사
영상 검사
컴퓨터 단층촬영(CT) 스캔
자기공명영상(MRI)
기타
성장호르몬 결핍증 시장 규모 : 치료별
시장 개요
약물치료
재조합 인간성장호르몬
인간 하수체 추출물
수술
성장호르몬 결핍증 시장 규모 : 투여 경로별
시장 개요
정맥내
근육내
기타
성장호르몬 결핍증 시장 규모 : 최종사용자별
시장 개요
병원
홈케어
전문 클리닉
기타
성장호르몬 결핍증 시장 규모 : 유통 채널별
시장 개요
병원 약국
온라인 약국
소매 약국
성장호르몬 결핍증 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년대비 비교(2022-2024년)
주요 기업 개요
Pfizer Inc.(USA)
Eli Lilly and Company(USA)
Novo Nordisk A/S(Denmark)
Ipsen S.A.(France)
Ascendis Pharma A/S(Denmark)
Ferring Pharmaceuticals(Switzerland)
OPKO Health Inc.(USA)
Genexine, Inc.(South Korea)
LG Chem Ltd.(South Korea)
Anhui Anke Biotechnology(China)
Teva Pharmaceutical Industries Ltd.(Israel)
JCR Pharmaceuticals Co., Ltd.(Japan)
Shanghai United Cell Biotechnology Co., Ltd.(China)
Hanmi Pharmaceutical Co., Ltd.(South Korea)
Strongbridge Biopharma plc(USA)
GeneScience Pharmaceuticals Co., Ltd.(China)
Cipla Limited(India)
BIOCAD(Russia)
Krka, d. d.(Slovenia)
OPBIO Factory Co., Ltd.(South Korea)
결론과 제안
LSH
영문 목차
영문목차
Growth Hormone Deficiency Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 3.9 billion in 2024 to USD 5.99 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).
The rising incidence of growth hormone deficiency (GHD), driven by factors like genetic disorders, brain injuries, and specific medical treatments, is significantly boosting the demand for growth hormone therapies. Data from the National Center for Biotechnology Information (NCBI) indicates that approximately 1 in every 3,500-4,000 children in the UK is affected by pediatric GHD, highlighting a growing need for effective treatments. This increasing prevalence is catalyzing industry expansion, with robust research and development at the forefront. A notable advancement occurred in February 2022 when Pfizer and OPKO received European Union marketing authorization for their Once-Weekly NGENLA(TM) (somatrogon) Injection, marking an important milestone in the growth hormone therapy landscape and further cementing the industry's growth trajectory.
Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Growth Hormone Deficiency Market is segmented by Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Diagnosis, the market is segmented into Blood Tests, Imaging Tests, Computerized tomography (CT) scans, Magnetic resonance imaging (MRI) and Others. Based on Treatment, the market is segmented into Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery. Based on Route of Administration, the market is segmented into Intravenous, Intramuscular and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Growth Hormone Deficiency Market
One of the key market drivers for the global growth hormone deficiency market is the increasing prevalence of growth hormone deficiency and related disorders among children and adults. This rise is partly attributed to better diagnosis and awareness, leading to earlier identification and treatment. Additionally, lifestyle factors, such as sedentary habits and rising obesity rates, contribute to hormonal imbalances, further fueling the need for growth hormone therapies. As healthcare providers continue to emphasize the importance of addressing growth issues and improving quality of life, the demand for effective growth hormone treatments is expected to grow significantly in the coming years.
Restraints in the Growth Hormone Deficiency Market
The market for Growth Hormone Deficiency faces significant restraints, primarily due to the high costs associated with Human Growth Hormone (HGH) therapy. This financial burden limits accessibility for various patient groups and places considerable strain on healthcare systems. A 2022 medical journal study highlighted the extensive financial challenges faced by patients and healthcare providers alike, emphasizing the need for more affordable treatment options. Addressing these economic hurdles is crucial for enhancing access to HGH therapy, prompting calls for the development of cost-effective solutions and pricing reforms to ensure that more individuals can benefit from necessary treatments without extreme financial hardship.
Market Trends of the Growth Hormone Deficiency Market
The Growth Hormone Deficiency (GHD) market is experiencing a noteworthy shift driven by innovative advancements in drug delivery systems. The introduction of wearable patches, needle-free devices, and autoinjectors enhances patient convenience and compliance, transforming how growth hormone therapies are administered. Additionally, the rise of long-acting formulations and implantable devices allows for extended-release options, significantly reducing the frequency of dosing. These innovations not only improve treatment efficacy but also elevate patient experiences, enabling wider accessibility to essential therapies. As the industry embraces these developments, the GHD market is set for robust growth, highlighting significant opportunities for pharmaceutical companies and healthcare providers alike.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Global Growth Hormone Deficiency Market Size by Type & CAGR (2025-2032)
Market Overview
Pediatric Growth Hormone Deficiency
Adult Growth Hormone Deficiency
Global Growth Hormone Deficiency Market Size by Diagnosis & CAGR (2025-2032)
Market Overview
Blood Tests
Imaging Tests
Computerized tomography (CT) scans
Magnetic resonance imaging (MRI)
Others
Global Growth Hormone Deficiency Market Size by Treatment & CAGR (2025-2032)
Market Overview
Pharmacological Therapy
Recombinant Human Growth Hormone
Human Pituitary Gland Extracts
Surgery
Global Growth Hormone Deficiency Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Intravenous
Intramuscular
Others
Global Growth Hormone Deficiency Market Size by End User & CAGR (2025-2032)
Market Overview
Hospitals
Homecare
Specialty Clinics
Others
Global Growth Hormone Deficiency Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Global Growth Hormone Deficiency Market Size & CAGR (2025-2032)
North America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
US
Canada
Europe (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
GCC Countries
South Africa
Rest of Middle East & Africa
Competitive Intelligence
Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
Company Details
Product Portfolio Analysis
Company's Segmental Share Analysis
Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
Pfizer Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Eli Lilly and Company (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Novo Nordisk A/S (Denmark)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Ipsen S.A. (France)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Ascendis Pharma A/S (Denmark)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Ferring Pharmaceuticals (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
OPKO Health Inc. (USA)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Genexine, Inc. (South Korea)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
LG Chem Ltd. (South Korea)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Anhui Anke Biotechnology (China)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
JCR Pharmaceuticals Co., Ltd. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
Shanghai United Cell Biotechnology Co., Ltd. (China)
